Nektar Therapeutics (NKTR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NKTR Revenue Growth
Revenue Breakdown (FY 2025)
NKTR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
NKTR Revenue Analysis (2014–2025)
As of May 8, 2026, Nektar Therapeutics (NKTR) generated trailing twelve-month (TTM) revenue of $55.2 million, reflecting significant decline in growth of -25.3% year-over-year. The most recent quarter (Q4 2025) recorded $21.8 million in revenue, up 85.0% sequentially.
Looking at the longer-term picture, NKTR's 5-year compound annual growth rate (CAGR) stands at -18.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $1.19 billion in 2018.
Revenue diversification analysis shows NKTR's business is primarily driven by Non Cash Royalty Revenue Related To Sale Of Future Royalties (99%), and License Collaboration And Other Revenue (1%). With over half of revenue concentrated in Non Cash Royalty Revenue Related To Sale Of Future Royalties, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HALO (+37.6% YoY), ARWR (+14.1% YoY), and ALNY (+82.6% YoY), NKTR has underperformed the peer group in terms of revenue growth. Compare NKTR vs HALO →
NKTR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NKTRCurrent | $55M | -25.3% | -18.4% | -236.8% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% |
NKTR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $55.2M | -43.9% | $55.2M | 100.0% | $-130,770,999 | -236.8% |
| 2024 | $98.4M | +9.2% | $67.7M | 68.8% | $-105,198,000 | -106.9% |
| 2023 | $90.1M | -2.1% | $53.5M | 59.3% | $-137,425,000 | -152.5% |
| 2022 | $92.1M | -9.7% | $70.4M | 76.5% | $-240,236,000 | -261.0% |
| 2021 | $101.9M | -33.4% | $77.0M | 75.6% | $-446,103,000 | -437.8% |
| 2020 | $152.9M | +33.4% | $133.4M | 87.3% | $-379,922,000 | -248.5% |
| 2019 | $114.6M | -90.4% | $93.2M | 81.4% | $-440,035,000 | -383.9% |
| 2018 | $1.19B | +287.8% | $1.17B | 98.0% | $687.9M | 57.6% |
| 2017 | $307.7M | +86.0% | $277.2M | 90.1% | $-59,642,000 | -19.4% |
| 2016 | $165.4M | -28.3% | $135.2M | 81.7% | $-112,855,000 | -68.2% |
See NKTR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKTR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKTR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKTR — Frequently Asked Questions
Quick answers to the most common questions about buying NKTR stock.
Is NKTR's revenue growth accelerating or slowing?
NKTR revenue declined -25.3% year-over-year, contrasting with the 5-year CAGR of -18.4%. TTM revenue fell to $55M. This reverses the prior growth trend.
What is NKTR's long-term revenue growth rate?
Nektar Therapeutics's 5-year revenue CAGR of -18.4% reflects the variable expansion pattern. Current YoY growth of -25.3% is below this long-term average.
How is NKTR's revenue distributed by segment?
NKTR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.